results
Sanofi confirm 2016 outlook with Q1 results, EPS rises 5.3%
April 29, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2016, Q1, Sanofi, earnings, outlook, results
Sanofi (EPA: SAN) has confirmed its outlook for 2016 with the publication of their first quarter results, with earnings per …
AstraZeneca Q1 earnings down 12%; maintains FY view
April 29, 2016Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Q!, earnings, outlook, profits, q, results
UK drugmaker AstraZeneca (LSE: AZN) on Friday reported a 12% drop in first-quarter earnings and said it plans to streamline …
GlaxoSmithKline Q1 earnings up 14% on new product sales
April 27, 2016Research and Development, Sales and Marketing GSK, GlaxoSmithKline, Q1, earnings, results, revenue, sales
GlaxoSmithKline (LSE: GSK) reported a 14% rise in first-quarter earnings driven by demand for new drugs. The UK drug firm …
Baxter hikes 2016 earnings view driven by strong Q1 results
April 27, 2016Research and Development, Sales and Marketing Baxalta, FY, Q1, baxter, earnings, outlook, results, revenue
Baxter International (NYSE: BAX) reported better-than-expected first-quarter profits and raised its earnings outlook for 2016. The company now sees earnings …
Bayer’s earnings beat estimates as blockbusters shine
April 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales
Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …
Biogen Q1 profits rise boosted by Tecfidera sales
April 22, 2016Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera
Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter …
Novartis Q1 earnings drop as cancer drug sales falter
April 21, 2016Business Services, Sales and Marketing Financial, Novartis, earnings, first quarter, results
Swiss drugmaker Novartis (SIX: NOVN) on Thursday reported a 13% drop in net income for the first quarter on the …
Boehringer Ingelheim posts 11% rise in FY15 sales boosted by diabetes business
April 20, 2016Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, FY, earnings, forecasts, outlook, results
Boehringer Ingelheim reported 11% jump in sales for 2015 driven by its diabetes business and said for 2016 it sees …
J&J raises FY outlook, Q1 beats estimates
April 20, 2016Business Services, Research and Development, Sales and Marketing Financial, Johnson & Johnson, Q1, earnings, results, revenue, sales
Healthcare giant Johnson & Johnson (NYSE: JNJ) raised its full-year outlook and posted first-quarter earnings ahead of estimates despite currency headwinds. …
Roche reports 5% rise in Q1 sales boosted by cancer drugs
April 19, 2016Manufacturing and Production, Sales and Marketing Q1, Roche, earnings, oncology drugs, results
Oncology drug maker Roche (VTX: ROG) on Tuesday reported 5% increase in first-quarter sales driven by cancer drugs. The company …
Valeant cuts 2016 sales, earnings outlook; shares plunge over 47%
March 15, 2016Business Services, Manufacturing and Production, Sales and Marketing Valeant Pharma, fourth quarter, full year, results
Valeant Pharmaceuticals Inc (NYSE: VRX) cut its outlook for the first-quarter of 2016 and posted a loss for the final …
Boehringer assures future growth following sales drop
April 23, 2015Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results
Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …
Merck: ‘2014 revenues will be down’
February 7, 2014Sales and Marketing Frazier, Merck, Simponi, Singulair, isentress, q4, results
Merck is the latest pharma company to release figures suggesting 2013 was more of a struggle than it would like, …
AstraZeneca battling ‘headwinds’
February 7, 2014Sales and Marketing AstraZeneca, Soriot, farxiga, q4, results, xigduo
AstraZeneca is to shed another 550 jobs as its latest corporate restructure takes shape, bringing to 5,600 the number of …
